雄激素非依赖性前列腺癌的当前化疗方法。

Current chemotherapeutic approaches for androgen-independent prostate cancer.

作者信息

Rumohr Jon A, Chang Sam S

机构信息

Vanderbilt University Medical Center, Department of Urologic Surgery, A-1302 Medical Center North, Nashville, TN 37232-2765, USA.

出版信息

Curr Opin Investig Drugs. 2006 Jun;7(6):529-33.

PMID:16784023

Abstract

This review describes the current state of chemotherapy for androgen-independent prostate cancer. Landmark clinical trials, including TAX 327, a randomized trial comparing docetaxel and prednisone with mitoxantrone and prednisone, and SWOG 9916, a randomized clinical trial comparing docetaxel and estramustine with mitoxantrone and prednisone, are reviewed. Novel combination therapies, involving taxane administered with compounds such as calcitrol and thalidomide, newer cytotoxic agents, vaccine therapies, and targeted modalities are also detailed. This review mainly focuses on agents with activity in phase II/III clinical trials.

摘要

本综述描述了去势抵抗性前列腺癌化疗的当前状况。对一些具有里程碑意义的临床试验进行了综述，包括TAX 327（一项比较多西他赛联合泼尼松与米托蒽醌联合泼尼松的随机试验）和SWOG 9916（一项比较多西他赛联合雌莫司汀与米托蒽醌联合泼尼松的随机临床试验）。还详细介绍了新型联合疗法，包括将紫杉烷与诸如骨化三醇和沙利度胺等化合物联合使用、新型细胞毒性药物、疫苗疗法以及靶向治疗方法。本综述主要关注在II/III期临床试验中具有活性的药物。